World Precision Medicine (China) Summit 2016

World Precision Medicine (China) Summit 2016

 Gaining a Clearer Perspective into Innovation Trends,

Technology Advancements and Cooperation Opportunities

December 3-4,  / Shanghai Everbright International Hotel, PRC

 

On January 30, 2015, US President Obama launched the Precision Medicine Initiative and precision medicine has become the spotlight of global healthcare industry. Meanwhile, Chinese President Xi Jinping appointed the NHFPC and the MOST to establish the National Precision Medicine Strategic Expert Committee. Chinese Precision Medicine Plan has been included in the 13^th FYP for national major science & technology specific projects and precision medicine has become China’s national strategy. Currently, global precision medicine market values about $60 billion and the growth rate is estimated up to 15% from 2015 to 2020, which equals almost 3-4 times of the entire pharmaceutical industry. Stimulated by favorable policies and funding environment, and with the rapid technology advancements of NGS, gene editing, biochip, IVD, liquid biopsy, anti-body drugs R&D, cell immunotherapy, big data and inspiring research breakthroughs, precision medicine industry is embracing new development opportunities. 

 

In such context, “World Precision Medicine (China) Summit 2016”, co-organized by Sino-American Pharmaceutical Professionals Association (SAPA), Shanghai Fenglin life Healthcare Development Co., Ltd. and Healife Group will be held on December 3-4, 2016 in Shanghai, China. Under the theme of “Gaining a Clearer Perspective into Innovation Trends, Technology Advancements and Cooperation Opportunities ”, WPMCS2016 brings together 1,000+ senior executives from Government, academy, hospitals, big pharmas, life sciences & biotech companies,  CROs, VCPEs  to discuss the redhot topics such as China-US precision medicine market outlook and evolving regulatory landscape , big data, advanced technologies and investment opportunities, biobank & cohort study, cell immunotherapy, genetic testing &IVD, innovation & cooperation of antibody drugs, clinical therapy of tumor. Geographically, besides the delegates from Mainland China, a large number will be travelling from the United States, Europe, Israel, Japan, Korean, Singapore, Taiwan and many other countries and areas. WPMCS2016 offers an ideal balance of scientific sessions and networking opportunities, and features 100+ one-to-one meetings, 80+ eminent speakers from global precision medicine fraternity, 50+ exhibitors, 5 parallel symposiums, 2 interactive panel discussions, 1 project financing roadshow matching and our specially designed post-event US precision medicine overseas business trip.

 

More information about the Summit, Please visit the official event website: http://www.wpmcs.com.cn/

 

Any question, pls contact Ms. Karen YAU Tel: 18918108518   Email: karenyou@healife.com

 

Organizing Committee:

• Consigned by:

Science and Technology Commission of Shanghai Municipality

Shanghai Municipal Food and Drug Administration

Shanghai Municipal Commission of Commerce

 

• Organized by:

Sino-American Pharmaceutical Professionals Association

Shanghai Fenglin life Healthcare Development Co., Ltd.

Healife Group Co., Ltd.

 

• Co-organized by:

Shanghai Center of Biomedicine Development

Shanghai Biopharmaceutics Industry Association

Shanghai Clinical Research Center

Shanghai Medical Instrument Trade Association

Shanghai Institute of Medical Quality

Fitestone

 

• Recommend by:

European Society for Radiotherapy & Oncology

 

• Endorsers:

International Cancer Research Center

European Alliance for Personalized Medicine

US Chinese Anti-Cancer Association

Chinese Biopharmaceutical Association - USA

Precision Medicine Branch of China Medical Biotech Association

China Precision Medicine Technology Innovation Alliance

China Strategic Alliance of Technology Innovation for Minimally Invasive Tumor Therapy

 

Eminent Sponsors：

 

WPMCS2016 Features：

 

1,000+ senior participants from global precision medicine fraternity

500+ senior representatives from research institutions and hospitals

100+ one-to-One Meetings

80+ world-class eminent speakers

50+ exhibitors

5 parallel symposiums on: Genetic Testing &IVD, Biobank &Cohort Study, Innovation & Cooperation of Antibody Drugs, Clinical Therapy of Tumor, Cell Therapy

1 half-day project financing roadshow matching focusing on Gene Sequencing, Biochip, Liquid Biopsy, Anti-body Drugs and Cell Therapy  

Plus post-event US precision medicine business trip

 

Agenda Framework：

 

Day One 3 Dec. Morning Plenary Session: China-US Precision Medicine Market Outlook and Evolving Regulatory Landscape
Day One 3 Dec. Afternoon Plenary Session: Big Data, Advanced Technologies and Investment Opportunities
Day Two 4 Dec. Morning Parallel Symposiums I-III
Parallel Symposium I: Genetic Testing &IVD	Parallel Symposium II: Clinical Therapy of Tumor	Parallel Symposium III: Antibody Drugs R&D
Day Two 4 Dec. Afternoon Parallel Symposiums IV-VI
Parallel Symposium IV: Biobank&Cohort Study	Parallel Symposium V: Cell Therapy	Parallel Symposium VI: Project Financing Road Show

 

Eminent Speakers (Inviting)：

 

• Government Officials&/Association Leaders:

China Food and Drug Administration (CFDA) Deputy Director, Wu Zhen

China National Center for Biotechnology Development Policy Coordination Director, Qiu Hongwei

China National Health and Family Planning Commission Science and Technology Director, Maxu

National Institutes of Health (NIH) Director, Francis Collins Ph.D

FDA China Office Director, Leigh Verbois Ph.D

SAPA President, Johnson& Johnson Scientific Director/Janssen Fellow, Dai Weiguo Ph.D

USCACA Chairman, Wei Zhang ph.D

ISBER Past-President, Jim Vaught ph.D

AABB Center for Cellular Therapies & Research Vice President, Naynesh Kamani

ICRC Founder, Yehia Abugabal ph.D

EAPM Executive Director, Denis Horgan

Shanghai Fenglin Life Healthcare Development Chairman, Wu Yinfei

Fudan University Public Health School Vice President& Key Lab of Health Technology Assessment Ministry of Health Director, Chen Yingyao

 

• University Professors /Research/Medical Institutions’ Experts:

Fudan University Vice President, Jin Li Academician

Shanghai Cell Therapy Research Institute Director, Qian Qijun

Institute of Biophysics, Chinese Academy of Sciences Researcher, Chen Runsheng Academician

Zhongshan Hospital Fudan University President, Fan Jia

Shandong Cancer Hospital President Yu Jinming

Tianjin Cancer Hospital President& Tumor Precision Medicine Big Data Center Director, Wangping

The Affiliated Hospital of Nanjing University Medical School Vice President/ Tumor Center Director, Liu Baorui

Ruijin Hospital Vice President, Ning Guang Academician

US National Cancer Institute Director, Dimiter S Dimitrov

Mayo Clinic Technology Assessment Group Center for Individualized Medicine Chairman, David Smith

Wake Forest University Baptist Comprehensive Cancer Center Director, Boris Pasche

University of Texas MD Anderson Cancer Center Tenured Associate Professor, Liang Han

University of Colorado Division of Medical Oncology Distinguished Professor, Paul Bunn

Cancer Research UK Precision Medicine Head, Rowena Sharpe

Sweden Karolinska Institute Medical School Professor, Roman A. Zubarev

German university of Brunswick Professor, Stefan Dübel

National Taiwan University Professor, Eric Y. Chuang

Seoul National University Hospital Professor& Korea National Academy of Sciences Director, Yung-Jue Bang

Ministry of Health, Xiangya Hospital Central South University, Key Laboratory of Cancer Proteomics Professor, Zhan Xianquan

Shanghai Center for Drug Discovery & Development Director, Shao Liming

Tongji University School of Medicine Dean& Professor, Xu Guotong

Shanghai Institutes for Biological Sciences Director, Li Yixue

Jiangsu Province Hospital Vice President, Zhao Jun

Peking University Health Science Center School of Public Health Professor, Li Liming

Fudan University Biomedical Sciences Institutes Professor, Liu Lei

Xiamen University TMRC &CTCTCT Professor& Executive Director, Zeng Jimeng

Hebei University of Science and Technology Associate Professor, Han Chunyu

 

• Global Precision Medicine enterprises/VCPE Senior Executives

BGI Chairman, Wang Jian Academician

Illumina Greater China General Manager, Zhao Ruilin

Eli Lilly and Company China Drug Development Senior Vice President, Kerry Blanchard

Johnson& Johnson Asia-Pacfic Innovation Center Senior Director, Xia Mingde

IMB Watson Health China Head & Innovation Division CTO, Wu Yiduo

Alibaba Cloud Computing President & Alibaba Group Vice President, Hu Xiaoming

Intel Health and Life Science General Mangager Asia- Pacific Region, Carl Li

Qiagen General Manager, Nick Zhang

CapitalBio Corporation Associate Researcher, Guo Hongyan

Amgen Vice President of Global R&D, Zhang Mingqiang

Genentech Executive Vice President, Global Development and Chief Medical Officer, Sandra Horning

LabCorp Chairman & CEO, David King

Roche Diagnostics Principle Scientist Jan Kuentzer

Merck Vice President, Head of Translational Medicine, Robert Plenge

Regeneron Phamarceuticals, Regeneron Laboratories &Chief Science Officer, President, George Yancopoulos

GSK Oncology SVP, TA Head Oncology R&D, Chris Carpenter

Macrogen, NGS Division, General Manager, Bon-Chao Kim

Jiangsu Hengrui Medicine Co, .Ltd, Vice President of Global R&D, Zhang Lianshan

Seattle Genetics CMO & EVP, Research and Development, Jonathan Drachman

CP Guojian Pharm President, Wang Junlin

Genor BioPharma CEO, Zhou Xinhua

CloudHealth Genomics Partner& President, Jin Gang

Roche Diagnostics China CEO, Huang Boxing

Burning Rock Dx Founder, Han Yusheng

Dian Diagnostics Chairman, Chen Haibin

Berry Genomics Chairman, Gao Yang

Haplox Founder & CEO, Xu Mingyan

BVCF Fund, Founding Partner, Yang Zhi

Sequoia Capital Partner, Chen Penghui

GTJA Investment Group Executive Partner, Wang Haijiao

V-Stone Investment Partner, Yu Tiecheng

Touwho CEO, Zhao Yanyu

Firestone Founder & CEO, Yang Hongfei